Krish Patel, Director of the Lymphoma Research Program at the Sarah Cannon Research Institute, shared on LinkedIn:
“Long awaited…
Excited to see in press our multi-center effort of CD19 allo iPSC CAR-NK (FT596) in B-cell lymphomas!
Important proof of concepts and signals from this study:
-very low CRS.
-no ICANS.
-multi dose off shelf treatment.
-durable responses in challenging histologies.
Lots still to do to advance the field of allo CAR-NK: we need further improved response rates, optizimation of dosing and lymphodepletion approaches, but this is a good place to move forward from.
I am optimistic that our field will continue to make advancements here!”
Authors: Armin Ghobadi, Veronika Bachanova, Krish Patel, Jae H Park, Ian Flinn, Peter A Riedell, Carlos Bachier, Catherine S Diefenbach, Carol Wong, Cara Bickers, Lilly Wong, Deepa Patel, Jode Goodridge, Matthew Denholt, Bahram Valamehr, Rebecca L Elstrom, Paolo Strati
